What it takes: Getting a HIV vaccine in our lifetime(s)

By Dázon Dixon Diallo, DHL MPH

Some might say 37 years is long enough. They might think that within nearly four decades we should have found a way to globally vaccinate against one of the most elusive, smart and resilient viruses in the history of public health. I would say, Is that so? Why would you think that?

From the earliest days of the AIDS epidemic, scientists, clinicians and community activists have been working, most often together, and sometimes not, on the pursuit of an effective vaccine that would essentially end the HIV pandemic, and provide a universal prevention intervention for generations to come.

In that time, we have benefitted from the advances in HIV treatment and prevention science, with the advent of Treatment as Prevention, Pre-exposure Prophylaxis (PrEP), Perinatal Transmission Prevention and subsequent successes with co-morbidities like Hepatitis C and some cancers. Despite these incredible advances in treatment and prevention, we still need a vaccine.

We have witnessed the effects of providing comprehensive information, services and supports that enable people to prevent HIV, to live well with HIV and to help others get into care early in their diagnosis – and we still need a vaccine.

We have charged and changed governments to make better policy and implement progressive social change to eliminate some of the barriers to treatment, care and prevention – and we still need a vaccine.

The start and stop progress that has defined the field of HIV Vaccine research has been consistently rescued by hope – the hope of scientists that they can find the right molecules, the hope of communities of advocates and activists that our fight will one day end, and the hope of millions of people living with HIV that their struggles to surmount stigma and to live in dignity will win the day.

We all owe debts of gratitude to our brothers, sisters and comrades on the African Continent.

As much as we have engaged communities to increase research literacy in order to engage more effectively with the science, we have a long way to go to engage researchers to increase community literacy in order to more effectively design trials and tools that have value and meaning to folks who need them the most.

On this HIV Vaccine Awareness Day, as an activist who has been in this fight for 33 years, I am giving honor and thanks to the tens of thousands of people, especially the African souls who have put their bodies and their lives on the line to find the vaccine that will work for billions around the world. Without the involvement of people who are carrying the overwhelming burden of the epidemic, we would have never gotten this far.

And with our eye on the prize of ending the epidemic as we know it, we must remain humble, respectful and stand in solidarity with African peoples as they lead us through the next stages of advancement and discovery in HIV Vaccine Research.

For me, this and every HIV Vaccine Awareness Day belongs to those research participants, and to all of the researchers who have learned how to build solidarity and respect the critical, indispensable role of indigenous expertise, of the lived experience.

The Rastafarians have always said that “Africa awaits its creators”, meaning that Africa’s problems will be resolved with African solutions – by people of African Descent wherever they are. I embrace this belief as the ultimate hope for us all.

Diallo is Founder/President, SisterLove USA/RSA

Keep up with NHVMAS activities on our social media platforms and join the conversation

Facebook: www.facebook.com/nhvmas

Twitter: @nhv_mas